Clinical trials: Influenza Virus Infection
Coronary Artery Diseases, Myocardial Infarction
The Efficacy of Influenza Vaccine in Reducing Cardiovascular Events in Patients With Coronary Artery Diseases
Influenza vaccine reduces the cardiovascular events in post-myocardial infarction (MI) patients and in those with stable angina (SA).
- Conditions
- Coronary Artery Diseases, Myocardial Infarction, Stable Angina
- Trial name
- IVCAD (NCT00607178)
- Testing
- influenza vaccine
- Where
- Iran
- Volunteers
- 300 people
- Sponsor
- Shahid Beheshti University of Medical Sciences
Influenza
Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age
A Phase III, Randomized, Observer-Blind, Controlled, Multicenter Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator…
- Trial name
- NCT02587221
- Testing
- MF59-adjuvanted Quadrivalent Subunit Inactivated Egg-derived Influenza Vaccine (aQIV), Non-Influenza Comparator (Boostrix)
- Where
- 89 sites in Bulgaria, Colombia and 10 more
- Volunteers
- 6,790 people, healthy volunteers welcome
- Sponsor
- Seqirus
Virus Diseases, RNA Virus Infections
Immunogenicity, Safety and Tolerability of a Plant-Derived Seasonal Virus-Like-Particle Quadrivalent Influenza Vaccine in Adults
A phase II trial multicenter, observer-blind, randomized, dose-ranging, placebo-controlled study to evaluate the immunogenicity, safety, and tolerability of a single intramuscular injection of plant-derived Seasonal VLP…
- Conditions
- Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases, Respiratory Tract Infections
- Trial name
- NCT02233816
- Testing
- Low dose of quadrivalent VLP vaccine, Medium dose of quadrivalent VLP vaccine, High dose of quadrivalent VLP vaccine
- Where
- 2 sites in United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Medicago
Pregnant Women, Influenza
Flucelvax Pregnancy Registry
The goal of the registry is to develop a better understanding of the safety of Flucelvax in women and their offspring who were exposed to the vaccine during pregnancy
- Trial name
- NCT02258178
- Testing
- Flucelvax (cTIV)
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Seqirus
Bird Flu, Avian Influenza
A Phase I Study to Evaluate the Safety, Reactogenicity, and Humoral Immune Responses to an Inactivated H5N1 Influenza Vaccine
The focus of this study is to evaluate the safety, reactogenicity and humoral immune responses of the study vaccine when administered at the dose of 7.5 µg HA, 15 µg HA, or 30 µg HA to human subjects.
- Conditions
- Bird Flu, Avian Influenza, Influenza A(H5N1)
- Trial name
- NCT01675284
- Testing
- AT-301
- Where
- Taiwan
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Medigen Biotechnology Corporation
Influenza
Immunogenicity, Safety and Tolerability of Two Doses of FLUAD-H5N1 Influenza Vaccine in Adult and Elderly Subjects
This study is designed to evaluate the immunogenicity, safety and tolerability of 2 doses of FLUAD-H5N1 vaccine compared to 2 doses of trivalent, interpandemic FLUAD, each administered 3 weeks apart.
- Trial name
- NCT00434733
- Testing
- Pandemic influenza vaccine
- Where
- Poland
- Volunteers
- 4,400 people, healthy volunteers welcome
- Sponsor
- Novartis
Upper Respiratory Tract Infection, COVID-19
Elderberry for Immune Support
The purpose of this study is to confirm and quantify the effects of ElderCraft® elderberry extract on immune health.
- Conditions
- Upper Respiratory Tract Infection, COVID-19, Flu, Flu Like Illness
- Trial name
- NCT05435144
- Testing
- Elderberry
- Where
- United States
- Volunteers
- 420 people, healthy volunteers welcome
- Sponsor
- Nutraceuticals Research Institute
Influenza
Immunogenicity and Safety of GSK Biologicals' (Pre-) Pandemic Influenza Candidate Vaccine
This trial will assess the immunogenicity and safety elicited by the adjuvanted GSK Biologicals' (pre-) pandemic influenza candidate vaccine in healthy Japanese adults.
- Trial name
- NCT00742885
- Testing
- Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted
- Where
- 2 sites in Japan
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
COVID-19, Influenza A
Sample Collection for Evaluation of the Panbio™ COVID-19/ Flu A&B Rapid Panel.
This study is designed as a prospective, multicentric, sample collection study. The collected samples will be used for diagnostic research, product development and validation of the Panbio™ COVID-19/ Flu A\&B Rapid Panel for the…
- Conditions
- COVID-19, Influenza A, Influenza Type B
- Trial name
- NCT05354115
- Testing
- Nasal and Nasopharyngeal Sampling of the Panbio™ COVID-19/ Flu A&B Rapid Panel
- Where
- United States
- Volunteers
- 676 people
- Sponsor
- Abbott Rapid Dx
Influenza, Pandemic Influenza
Phase 1 Study of a H5N1 Influenza Vaccine (Reverse Genetic Reassortant)
The objectives of this study are to assess the dose-related safety and immunogenicity of six different dose levels of inactivated, Vero cell-derived reverse genetic reassortant A/H5N1/Indonesia/05/2005 influenza vaccine in a…
- Trial name
- NCT00783926
- Testing
- H5N1 Influenza Vaccine, Whole virion, Vero cell-derived, Inactivated Influenza Vaccine, non-adjuvanted (reverse genetic reassortant/H5N1 hemagglutinin antigen)
- Where
- 6 sites in United States
- Volunteers
- 422 people, healthy volunteers welcome
- Sponsor
- Alachua Government Services, Inc.
Influenza Vaccine
Safety and Immunogenicity of Cam2020 M2SR H3N2 Monovalent Influenza Vaccine Alone or With Licensed IIV in Older Adults
This is a randomized, double-blind, double-dummy, placebo-controlled Phase 1b study evaluating the safety and immunogenicity of the investigational Cam2020 M2SR H3N2 influenza vaccine delivered IN alone or concomitantly with…
- Trial name
- NCT05163847
- Testing
- Cam2020 M2SR H3N2 influenza vaccine, Fluzone HD IIV
- Where
- 6 sites in United States
- Volunteers
- 303 people, healthy volunteers welcome
- Sponsor
- FluGen Inc
Influenza
Study of the Influenza Vaccine (Split Virion, Inactivated) Northern Hemisphere 2009-2010 Formulation (Intradermal Route)
This study is in support of the annual application for the variation of the vaccine strains for a marketing authorisation. Objectives: To evaluate compliance, in terms of immunogenicity, of the corresponding strength of the…
- Trial name
- NCT00945438
- Testing
- Influenza virus vaccine 2009-2010 formulation
- Where
- 2 sites in France
- Volunteers
- 131 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza Vaccine, Behavioral Intervention
Limits of the Social Benefit Motive Among High-risk Patients: a Field Experiment on Influenza Vaccination Behaviour
Influenza vaccine uptake remains low worldwide, inflicting substantial costs to public health and health systems. Messages promoting social welfare have been shown to increase vaccination intentions, and it has been recommended…
- Conditions
- Influenza Vaccine, Behavioral Intervention, Self-benefit, Social-benefit
- Trial name
- NCT04230343
- Testing
- Self-benefit message, Other-benefit message
- Where
- Turkey (Türkiye)
- Volunteers
- 244 people
- Sponsor
- SB Istanbul Education and Research Hospital
Clinically Symptomatic Respiratory Illness
Effect of RTB101 on Illness Associated With Respiratory Tract Infections in the Elderly
The purpose of this study is to determine if RTB101 prevents illness associated with respiratory tract infections in people ≥65 years of age.
- Trial name
- NCT04139915
- Testing
- Dactolisib
- Sponsor
- Restorbio Inc.
Seasonal Influenza, Cough
Safety Study of IV Peramivir in Hospitalized Subjects With Confirmed or Suspected Influenza
This is a Phase 3, open-label, randomized study of the antiviral activity, safety, and tolerability of intravenous Peramivir in hospitalized subjects with confirmed or suspected influenza infection.
- Conditions
- Seasonal Influenza, Cough, Sore Throat, Nasal Congestion
- Trial name
- NCT00957996
- Testing
- Peramivir
- Where
- 110 sites in United States, Australia and 4 more
- Volunteers
- 234 people
- Sponsor
- BioCryst Pharmaceuticals
Influenza
Higher Dose Intradermal H5 Vaccine
This study will compare the influenza A/H5N1 virus vaccine given by injection in the muscle versus injection in the skin in healthy adults.
- Trial name
- NCT00439335
- Testing
- Inactivated Influenza A Vaccine A/H5N1
- Where
- United States
- Volunteers
- 227 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Novel 2009 Influenza H1N1
Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Children, Adolescents and Adults (3 to 64 Years)
This study will evaluate the safety and immunogenicity of different combinations of A/H1N1 S-OIV (swine flu) vaccine in healthy young children, adolescents, and adults.
- Trial name
- NCT00973700
- Testing
- MF59-eH1N1_f, eH1N1_f
- Where
- Costa Rica
- Volunteers
- 784 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza
Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Healthy Pediatric Participants From Birth to < 1 Year With Influenza-Like Symptoms
This study will evaluate the safety, pharmacokinetics and efficacy of baloxavir marboxil in healthy pediatric participants from birth to <1 year with influenza like symptoms
- Trial name
- NCT03653364
- Testing
- Baloxavir Marboxil
- Where
- 27 sites in United States, Bulgaria and 7 more
- Volunteers
- 49 people
- Sponsor
- Hoffmann-La Roche
Seasonal Influenza
Safety and Immunogenicity of Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2010/2011, When Administered to Adult and Elderly Subjects
Influenza poses a significant threat to individual and public health, and influenza vaccination with a trivalent inactivated influenza vaccine is widely recommended to children, adults at risks and elderly.
- Trial name
- NCT01161264
- Testing
- Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2010/2011
- Where
- Germany
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza
Safety and Immunogenicity of Three Influenza Vaccines in Children Aged 4 Years Old to Less Than 18 Years Old
Evaluate safety and immunogenicity of three influenza vaccines in children ages greater than 4 years old to less than 18 years old.
- Trial name
- NCT01992107
- Testing
- QIVc, TIV1c, TIV2c
- Where
- 88 sites in United States
- Volunteers
- 2,333 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.